Ignite Creation Date:
2025-12-24 @ 9:17 PM
Ignite Modification Date:
2026-01-02 @ 6:06 AM
Study NCT ID:
NCT03390504
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-12-22
First Post:
2017-12-20
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
Sponsor:
Janssen Research & Development, LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-03-23
Start Date Type:
ACTUAL
Primary Completion Date:
2024-04-15
Primary Completion Date Type:
ACTUAL
Completion Date:
2026-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2017-12-20
First Submit QC Date:
None
Study First Post Date:
2018-01-04
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2025-04-28
Results First Submit QC Date:
None
Results First Post Date:
2025-05-14
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-04
Last Update Post Date:
2025-12-22
Last Update Post Date Type:
ESTIMATED